(Q43803456)

English

Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study

scientific article published on 21 July 2011

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

S L Silverman

1

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

A A Chines

2

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

D L Kendler

3

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

A W C Kung

4

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

C S Teglbjærg

5

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

D Felsenberg

6

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

N Mairon

7

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

G D Constantine

8

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

J D Adachi

9

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Bazedoxifene Study Group

10

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

language of work or name

0 references

publication date

21 July 2011

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Osteoporosis International

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

23

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

351-363

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Burden of osteoporosis

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1691-1

21 January 2018

Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1691-1

21 January 2018

Management of osteoporosis in postmenopausal women

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1691-1

21 January 2018

Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1691-1

21 January 2018

What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis?

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1691-1

21 January 2018

Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1691-1

21 January 2018

Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1691-1

21 January 2018

Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1691-1

21 January 2018

Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1691-1

21 January 2018

Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1691-1

21 January 2018

Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis The Study of Osteoporotic Fractures Research Group

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1691-1

21 January 2018

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1691-1

21 January 2018

Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1691-1

21 January 2018

Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1691-1

21 January 2018

Lasofoxifene in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1691-1

21 January 2018

Bone quality--the material and structural basis of bone strength and fragility

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1691-1

21 January 2018

Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1691-1

21 January 2018

Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1691-1

21 January 2018

Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1691-1

21 January 2018

Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1691-1

21 January 2018

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1691-1

21 January 2018

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1691-1

21 January 2018

Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1691-1

21 January 2018

Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1691-1

21 January 2018

Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1691-1

21 January 2018

The effects of bazedoxifene on mammographic breast density in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1691-1

21 January 2018

The revision of the Declaration of Helsinki: past, present and future

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1691-1

21 January 2018

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1691-1

21 January 2018

Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21779819

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/21779819

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Osteoporosis breaks bones and budgets

1 reference

https://pubmed.ncbi.nlm.nih.gov/21779819

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/21779819

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The burden of prevalent fractures on health-related quality of life in postmenopausal women with osteoporosis: the IMOF study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21779819

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation

1 reference

https://pubmed.ncbi.nlm.nih.gov/21779819

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00198-011-1691-1

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43803456&oldid=2206268881"